Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

VANCOUVER, and SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, reports financial results for the three months ended July 31, 2007 and an update on its programs.

UPDATE ON DRUG DEVELOPMENT PROGRAMS

Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide; prevention of catheter-related infections): A pivotal Phase III study is in progress in the United States under a Special Protocol Assessment (SPA) agreement with the US FDA and in Europe. This confirmatory Phase III trial is a randomized, Evaluation Committee-blinded study to assess the effectiveness of Omigard(TM) vs. 10% povidone-iodine for the prevention of central venous catheter-related infections. This ongoing trial is known as the Central Line Infection Reduction Study, or CLIRS trial.

On July 30, 2007 Cadence Pharmaceuticals, our North American and European development and commercialization partner for Omigard(TM), announced that the FDA had agreed with their plan to increase the number of patients to be enrolled in CLIRS trial from 1,250 to 1,850. Cadence also announced that in June 2007 it completed enrollment of the original target of 1,250 patients in this clinical trial. Cadence expects they will complete enrollment of the new goal of 1,850 patients in the second quarter of 2008. If the results of the CLIRS trial are positive, Cadence expects to submit an NDA for omiganan 1% gel in the first half of 2009.

Celgosivir (MX-3253; oral a-glucosidase I inhibitor; treatment of chronic hepatitis C virus infections): Final top-line results of a Phase II combination study in non-responder and partial responder patients were announced April 11, 2007, demonstrating proof-of-concept and evidence of clinical benefit when adding celgosivir to the current standard-of-care HCV therapy (pegylated interferon plus ribavirin) as compared to the active control treatment (standard-of-care
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... Gain recognition for leadership and ... the biotech industry. Nominations are now being accepted ... you by the Bio Supply Management Alliance ... management professionals for the past 7 years. , ... Biotech industry – Manufacturers, Service Providers, Material Suppliers, ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
(Date:7/24/2014)... rely on sophisticated equipment, trained personnel, and detection ... against terrorist attacks. A revolutionary new electronic chip ... their job much easier. , The groundbreaking nanotechnology-inspired ... Aviv University ,s School of Chemistry and Center ... Herzliya company Tracense, picks up the scent of ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
... Jessica N Ebright 1 and Catherine Bowes Rickman 1, 2, ... Biology, Duke University Medical Center, Durham, , NC 27710 ... , Duke University Medical Center, Box 3802, Durham, NC ... bowes007@duke.edu , , ...
... Julio E Celis 1 , Morten stergaard 1 , Pamela Celis 1 , Hanne ... 2 , 1 Department of Medical Biochemistry ... University of Aarhus, Aarhus, Denmark , 2 Department ... Bladder cancer comprises a broad spectrum of tumors that includes ...
... Diana Davis, Aiguo Zhang, Jim Torrence, and Emily Dale, Bio-Rad Laboratories,Inc., 2000 Alfred Nobel ... Introduction , ... The concentrations of analytes in these assays ... standard curve. A regression analysis is performed to derive , ...
Cached Biology Technology:Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 2Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 3Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 4Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 5Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 6Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 7Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 8Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 2Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 3Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 4Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 5Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 6Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 7Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 8Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 9Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 10Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 11Selection of Standards for Bio-Plex Cytokine Assays, Rev A 2Selection of Standards for Bio-Plex Cytokine Assays, Rev A 3Selection of Standards for Bio-Plex Cytokine Assays, Rev A 4Selection of Standards for Bio-Plex Cytokine Assays, Rev A 5Selection of Standards for Bio-Plex Cytokine Assays, Rev A 6Selection of Standards for Bio-Plex Cytokine Assays, Rev A 7Selection of Standards for Bio-Plex Cytokine Assays, Rev A 8
(Date:7/25/2014)... Ravi Birla, associate professor of biomedical engineering at ... textbook on tissue engineering and artificial organ development., ... a comprehensive guide to entering into the field ... and professor of biomedical engineering at UH, served ... said that while there are other published books ...
(Date:7/25/2014)... a complex congenital central nervous system disease that ... neural tubes during the embryonic phase. Many patients ... incontinence and neurocognitive retardation. Such problems decrease the ... Researchers at Ankara Physical Medicine and Rehabilitation Education ... in children with SB, using the Pediatric Evaluation ...
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3
... Researchers at Albert Einstein College of Medicine of Yeshiva ... single gene in living cells. In an unprecedented study, published in ... were able to follow, in real time, the process of gene ... molecules of messenger RNA (mRNA) that go on to ...
... A study of DNA rearrangements in roundworm chromosomes may offer ... tumors. A report of the research led by University ... was published in the April 22 online edition of the ... region of repetitive DNA sequence that protects the ends of ...
... Infection Research (HZI) in Braunschweig, Germany have discovered a new, ... cells: In this entry mode, the bacteria exploit the muscle ... cytoplasm. Thus, the strategies Salmonella use to infect ... World Health Organization, the number of Salmonella infections ...
Cached Biology News:Scientists observe single gene activity in living cells 2Study in roundworm chromosomes may offer new clues to tumor genome development 2Salmonella utilize multiple modes of infection 2
ERalpha (Ser 104/106)...
... while maintaining high cell viability , ... , Fast: less than one ... , Highly reproducible results from ... with the Bio-Rad Gene Pulser Xcell System ...
Agarose, pulse field, 250 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Biology Products: